

LANNETT CO INC  
Form 8-K  
March 23, 2009

**United States**  
**Securities and Exchange Commission**

Washington, DC 20549

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

Date of Report: **March 17, 2009**

**Lannett Company, Inc.**

(Exact Name of Registrant as Specified in its Charter)

**DE**  
(State or other  
Jurisdiction of  
Incorporation)

**001-31298**  
(Commission File Number)

**23-0787699**  
(IRS Employer  
Identification  
No.)

**9000 State Road, Philadelphia, PA 19136**

(Address of Principal Executive Offices)

Registrant's telephone number, including area code: **(215) 333-9000**

## Edgar Filing: LANNETT CO INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 8.01      Other Events

On March 17, 2009, Lannett Company, Inc. ( Lannett ) settled its suit (Civil Action No. 08-338 (JJF)) and all related litigation against KV Pharmaceuticals, DrugTech Corp., and Ther-Rx Corp (collectively KV ).

In light of the withdrawal of KV s innovator prenatal product, and the resulting anticipated decline in sales and declining market for written prescriptions, Lannett decided it was pointless to continue the litigation and entered into the settlement arrangement with KV. Pursuant to the settlement, Lannett will receive a license from KV and will become an authorized generic provider. During the terms of the license, Lannett will pay KV a royalty on all future sales of its OB NATAL prenatal product. Lannett will cease offering its prenatal product if and when the brand is restored to the marketplace.

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Lannett Company, Inc.  
(Registrant)

By: /s/ Arthur Bedrosian  
Arthur Bedrosian  
President and Chief Executive Officer

Dated: March 23, 2009